Glionova AB

Glionova Therapeutics is a privately held niche oncology company developing novel therapies for glioblastoma, the most common and lethal primary brain cancer. Glionova is a Swedish, privately held drug discovery and development company. Glionovas proprietary technology is based on the research of founding partners Prof Patrik Ernfors and Dr Lars Hammarstr_m.

Glionovas lead project is based on research from the Department of Medical Biochemistry and Biophysics at the Karolinska Institutet and the Swedish national research infrastructure organisation Chemical Biology Consortium Sweden.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.glionova.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Stradvagen 5B,,114 51
Stockholm
Sweden
Email
Contact Number
+46 70 540 6519

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/glionova-therapeutics” connections=”true” suffix=””]

In Dec 2014 _ Glionova Therapeutics, raised SEK 42 Mn (US$ 5.7 Mn) Series A financing. Its major investors are Novo Seeds, Industrifonden and HealthCap. Beside this Glinova also received SEK 4.95 Mn from Swedish innovation agency VINNOVA.